Olivia Carter
Professor of Psychology at The University of Melbourne
Data updated
Research Footprint
Olivia Carter appears in 7 tracked papers (2006–2026), most studied alongside Psilocybin, DMT and MDMA, across Healthy Volunteers, Safety & Risk Management and Neuroimaging & Brain Measures.
Most-cited paper: Effects of psilocybin on time perception and temporal control of behaviour in humans (245 citations).
Frequent co-authors: Franz Vollenweider, Felix Hasler and Paul Liknaitzky.
Background & Research
Olivia Carter is a Professor in the Melbourne School of Psychological Sciences at The University of Melbourne, where she heads the Human Experience Lab. Her research focuses on how neurotransmitter systems shape conscious experience, cognitive function, and perception in healthy individuals, with additional clinical interests in psychiatric populations and altered perception. She has co-authored multiple foundational psychedelic neuroscience papers, including studies of psilocybin’s effects on attention, time perception, and consciousness.
Key Impact
She is a prominent cognitive neuroscientist whose work has helped characterize psilocybin’s effects on attention, working memory, perception, and consciousness in healthy humans.
Collaboration Network
5 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Olivia Carter is associated with.
The University of Melbourne
The University of Melbourne is a leading public research university in Australia, with medical and psychological sciences programmes contributing to psychedelic and mental health research.
View stakeholder →Harvard University
Non-ProfitHarvard University hosts multiple psychedelic research initiatives including the Study of Psychedelics in Society and Culture (a $16M program), the MGH Center for the Neuroscience of Psychedelics, and the Harvard Law School POPLAR project addressing psychedelic policy reform. These programs span neuroscience, cultural studies, and legal advocacy to advance scientific and societal understanding of psychedelics.
View stakeholder →